DRUG(DRUG)
DRUG
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | — | $30M | — | — | — |
| Low | — | $30M | — | — | — |
| High | — | $30M | — | — | — |
| EBITDA Avg | — | $-65M | — | — | — |
| Low | — | $-88M | — | — | — |
| High | — | $-43M | — | — | — |
| EBIT Avg | — | $-65M | — | — | — |
| Low | — | $-88M | — | — | — |
| High | — | $-43M | — | — | — |
| Net Income Avg | $-24M | $-65M | $-65M | $-63M | $-45M |
| Low | $-28M | $-88M | $-90M | $-63M | $-45M |
| High | $-21M | $-43M | $-40M | $-63M | $-45M |
| EPS Avg | $-3.67 | $-8.87 | $-10.56 | $-9.14 | $-6.50 |
| Low | $-4.03 | $-12.74 | $-13.16 | $-9.14 | $-6.50 |
| High | $-3.03 | $-6.25 | $-5.81 | $-9.14 | $-6.50 |
| Analysts (Rev / EPS) | — / 5 | 7 / 5 | — / 6 | — / 2 | — / 2 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 |
|---|---|---|---|---|---|
| Revenue Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| EBITDA Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| EBIT Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| Net Income Avg | $-15M | $-16M | $-20M | $-23M | $-28M |
| Low | $-19M | $-20M | $-20M | $-23M | $-28M |
| High | $-11M | $-13M | $-20M | $-23M | $-28M |
| EPS Avg | $-1.51 | $-1.68 | $-2.07 | $-2.37 | $-2.83 |
| Low | $-1.94 | $-2.00 | $-2.07 | $-2.37 | $-2.83 |
| High | $-1.07 | $-1.34 | $-2.07 | $-2.37 | $-2.83 |
| Analysts (Rev / EPS) | — / 4 | — / 3 | — / 1 | — / 1 | — / 1 |